January 27th, 2011

End of an Era: Eugene Braunwald Steps Down, Marc Sabatine Assumes Chair of TIMI Group

Marc Sabatine has replaced Eugene Braunwald as the chairman of the TIMI study group. Braunwald, who has been the dominant figure in cardiology for many decades, is 81. Sabatine was appointed Vice Chairman of the TIMI group last summer and he assumed the chairman’s role on January 1.

Braunwald is not retiring and will continue to serve as chairman for individual trials already underway. Sabatine enjoys strong support within the TIMI group and within Brigham and Women’s Hospital. Although no public announcement of the change has been made, and Braunwald is still listed as the TIMI chairman on the TIMI website, the change has been widely known at the Brigham for some time. Industry sponsors of TIMI trials have also been informed of the change in leadership.

TIMI member Chris Cannon commented on Sabatine’s new role: “We are all thrilled to have one of cardiology’s best and brightest to lead the TIMI Study Group. Marc is a world-class clinical trialist who also does cutting-edge pharmacogenomics and metabolomics work. He is a superb clinician and has been recognized several times as outstanding teacher of the year here at Harvard. As our trials have grown in size and number, we are all delighted to have Marc lead our Academic Research Organization into the future.”

2 Responses to “End of an Era: Eugene Braunwald Steps Down, Marc Sabatine Assumes Chair of TIMI Group”

  1. C. Grant La Farge, A.B., M.D. says:

    My heartfelt congratulations to Dr. Braunwald for a marvelous career! We have all benefitted so much from his spirit and his expertise.
    Grant La Farge, M.D., F.A.C.C.
    Formerly, Harvard Medical School & Boston Children’s Hospital

    Competing interests pertaining specifically to this post, comment, or both:

  2. Congratulations, Eugene, for your superb job. I was so lucky to have had the opportunity to work with you in several trials and I do hope to continue to learn from your expertise in the future in the trials in which we are still involved. Thanks a lot, indeed